ArticleOncology letters2017
Upregulation of miR-520b promotes ovarian cancer growth.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- RNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer Analysis and Experimental Validation.Journal of Cancer · 2026Article
- Comprehensive Computational Assessment of SNAI1 and SNAI2 in Gastric Cancer: Linking EMT, Tumor Microenvironment, and Survival Outcomes.Cancer informatics · 2025Article
- Expression study of microRNA cluster on chromosome 19 (C19MC) in tumor tissue and serum of breast cancer patient.Molecular biology reports · 2023Article
- Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.Genes & diseases · 2022Review
- RNF216 Alleviates Radiation-Induced Apoptosis and DNA Damage Through Regulating Ubiquitination-Mediated Degradation of p53 in Glioblastoma.Molecular neurobiology · 2022Article
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma.Biomarker research · 2021Article
- Current Implications of microRNAs in Genome Stability and Stress Responses of Ovarian Cancer.Cancers · 2021Review
- Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.Human cell · 2021Article
- Small Non-Coding-RNA in Gynecological Malignancies.Cancers · 2021Review
- MiR-520b inhibits proliferation, migration and invasion in gallbladder carcinoma by targeting RAB22A.Archives of medical science : AMS · 2021Article
- Identification of Immune-Related Prognostic Biomarkers Associated with HPV-Positive Head and Neck Squamous Cell Carcinoma.Journal of immunology research · 2021Article
- MicroRNA-520b targets interlukin-2 to regulate the growth, metastasis and drug sensitivity of liver cancer cells.American journal of translational research · 2020Article
- MicroRNA-335 targets the MEK/ERK pathway to regulate the proliferation and metastasis of colon cancer.American journal of translational research · 2020Article
- MLK3 is a newly identified microRNA-520b target that regulates liver cancer cell migration.PloS one · 2020Article
- In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the most common gynecological malignant cancer in female genitalia. Dysregulation or dysfunction of microRNAs (miRs) contribute to cancer development. The role of miR-520b in ovarian cancer remains unclear. The present study investigated the role of miR-520b in ovarian cancer and determined that the expression levels of miR-520b in ovarian cancer tissues and cell lines were upregulated. By contrast, reverse transcription-quantitative polymerase chain reaction and immunohistochemistry revealed that the mRNA and protein expression levels of ring finger protein 216 (RNF216) were downregulated in ovarian cancer, indicating that there was a negative correlation between miR-520b and RNF216. In miR-520b-knockdown cells, downregulation of miR-520b reduced cell proliferation, while upregulation of miR-520b promoted cell proliferation. In addition, RNF216 was predicted by TargetScanHuman and was observed to be targeted by miR-520b. In conclusion, the present data indicated that high expression of miR-520b in ovarian cancer promoted cell growth via RNF216.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.